This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
T-DXd
AACR 2025 | April 25-29, 2025
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02)
Oral
T-DXd
AACR 2025 | April 25-29, 2025
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)
Poster
Dato-DXd
AACR 2025 | April 25-29, 2025
Osimertinib treatment drives expression of TROP2, and combination treatment with datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, enhances its efficacy in PDX models of EGFR mutant non small-cell lung cancer
Poster
Dato-DXd
AACR 2025 | April 25-29, 2025
Potent antitumor efficacy of Dato-DXd compared with sacituzumab govitecan in a brain metastasis mouse model of triple-negative breast cancer
Oral
Dato-DXd, T-DXd, Valemetostat
AACR 2025 | April 25-29, 2025
Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors
Mini-Oral
T-DXd
AACR 2025 | April 25-29, 2025
Serum proteomics analysis: Potential biomarkers and mechanisms of trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis (ILD)
Poster
T-DXd
AACR 2025 | April 25-29, 2025
The role of NHEJ/HR mediated DSB repair in cancer cell sensitivity to payload of T-DXd
Poster
Dato-DXd
AACR 2025 | April 25-29, 2025
The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 QCS-NMR
Pages:
1 2